Hostname: page-component-7479d7b7d-rvbq7 Total loading time: 0 Render date: 2024-07-11T01:15:22.344Z Has data issue: false hasContentIssue false
  • English
  • Français

Observations on the Dose Regime of Fluphenazine Decanoate in Maintenance Therapy of Schizophrenia

Published online by Cambridge University Press:  29 January 2018

D. A. W. Johnson
D. A. W. Johnson*
Affiliation:
Crumpsall Hospital, Manchester 8, and University of Manchester
Get access Rights & Permissions [Opens in a new window]

Summary

An analysis of the drug regimes prescribed to two separate groups of unselected schizophrenic patients indicates certain trends of clinical importance. The results demonstrate a need for the adoption of a personalized dose regime. The scatter of dose regimes found effective is too great to recommend a standardized approach to the prescription of L.A.P. injections.

Two other results of particular significance are that the dose of drug required to control symptoms can be gradually reduced in nearly half of patients, and that helpful trends in prescribing were identified that will help the clinician to abolish side-effects.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 126 , Issue 5 , May 1975 , pp. 457 - 461
Copyright
Copyright © Royal College of Psychiatrists, 1975 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Denham, J. & Adamson, L. (1971) The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients. Acta Psychiatrica Scandinavia, 47, 420–27.Google Scholar
Ebert, A. G. & Hess, S. M. (1965) Journal of Pharmacology and Experimental Therapeutics, 148, 412.Google Scholar
Hirsch, S. R., Gaind, R., Rohde, P. D., Stevens, B. C. & Wing, J. K. (1973) Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. British Medical Journal, i, 633–7.Google Scholar
Johnson, D. A. W. (1973) The side-effects of fluphenazine decanoate. British Journal of Psychiatry, 123, 519–22.CrossRefGoogle ScholarPubMed
Johnson, D. A. W. & Freeman, H. L. (1972) The long-acting tranquillizers. The Practitioner, 208, 395–400.Google ScholarPubMed
Johnson, D. A. W. & Freeman, H. L. (1973) Drug defaulting by patients on long-acting phenothiazines. Psychological Medicine, 3, 115–19.CrossRefGoogle ScholarPubMed
Laffan, R. J., High, J. P. & Burke, J. C. (1965) The prolonged action of fluphenazine enanthate in oil after depot injection. International Journal of Neuropsychiatry, 1, 300–306.Google Scholar
Neal, C. D. & Imlah, N. W. (1968) Fluphenazine decanoate: a second long-acting phenothiazine. British Journal of Social Psychiatry, 2, 178–86.Google Scholar
Van Praag, H. M. & Dols, L. C. W. (1973) Fluphenazine enanthate and fluphenazine decanoate: a comparison of their duration of action and motor side-effects American Journal of Psychiatry, 130, 801–804.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.